News

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.The World Health Organization (WHO) recently warned about the limited pipeline of new antibiotics for drug-resistant bacteria in a report based on a review published by WHO in 2022. The report found that only 12 new antibiotics entered the market between 2017 and 2021. Additionally, the report found that although 27 experimental antibiotics for critical bacterial infections are in clinical development, only 6 of those are considered different enough from existing antibiotics to potentially be used against drug-resistant pathogens without concern. Without a steady stream of novel antibiotics entering the pipeline and market, bacterial infections will become increasingly dangerous as bacteria continues to develop resistance to existing drugs.A new study from researchers at HDT Bio found that a new type of RNA vaccine against HIV and the Zika virus generated strong antibody responses in pregnant rabbits and their offspring. More studies will be necessary to confirm that vaccinating the mother alone is enough to protect against infection in the offspring, as well as to optimize vaccination timing and to see if the results can translate to humans. If successful, the vaccine could be an important tool in preventing mother-to-child transmission of these viruses and reducing the disease burden in newborns.A new study from researchers at Johns Hopkins University School of Medicine, supported by the US National Institutes of Health, found that HIV can persist in myeloid cells, a subset of white blood cells, in people who have been virally suppressed for years through antiretroviral therapy. The researchers emphasized that these findings challenge the long-held idea that these cells are short-lived, proving instead that these cells may contribute to an HIV reservoir and could be an important target in the development of a cure. Larger studies with more diverse participant pools will be needed to identify the proportion of people who show latent HIV in myeloid cells, as well as the mechanisms that replenish this reservoir over time.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.The World Health Organization (WHO) has announced efforts to fast-track the testing of vaccines and therapeutics for Marburg following the recent outbreaks in Tanzania and Equatorial Guinea. Those trials should get underway soon, said WHO officials, as four or five of the 28 potential candidates already have doses ready. In the meantime, contact tracing, isolation, and supportive care are being used to prevent transmission in the countries. A lack of laboratory capacity in Equatorial Guinea has so far prevented the timely identification of cases, but the Africa Centres for Disease Control and Prevention is working to provide technical support, as well as build infrastructure and capacity to improve testing, which will be important in upcoming trials.Last week, the US Centers for Disease Control and Prevention (CDC) warned about the recent, rapid spread of the drug-resistant fungus Candida auris, or C. auris, in health care facilities and highlighted the serious risk the fungus poses to immunocompromised individuals. C. auris is resistant to typical antifungal treatments, and developing a vaccine for the fungus would likely take many years. There are currently no approved vaccines for any form of fungal infections. One vaccine candidate, being developed with support from the US National Institutes of Health, is designed to be cross-protective against several fungal pathogens, potentially including C. auris, although a phase 1 clinical trial is over a year away.Executives at three of the world’s leading flu vaccine manufacturers—GSK, Moderna, and CSL Sequiris— have said that they are preparing the capacity to develop hundreds of millions of avian flu shots within months if a new strain of avian flu jumps to humans. The companies are already or will soon begin testing sample human vaccines that match the subtype currently circulating among birds and mammals. Sanofi has also expressed its readiness to begin production, alongside its stock of existing H5N1 vaccines. However, there is concern about how to ensure equitable global access to such vaccines in the case of an outbreak, given a substantial portion of doses are already reserved for wealthy countries through preexisting preparedness contracts.